Biden administration plans to buy enough of Pfizer's anti-Covid pill to treat 10M as U.S. regulators weigh whether to grant clearance of the medication, which has been found to greatly reduce hospitalizations and deaths from the virus.
whether to clear the medication, which has been found to greatly reduce hospitalizations and deaths from the coronavirus, according to a source familiar with the discussions.
The deal, along with another one worth $2.2 billion to buy more than 3 million doses of another antiviral pill to treat Covid, would give the U.S. another tool to fight the pandemic, and it could largely benefit those who remain unvaccinated, given that they are at significantly greater risk of hospitalization or death.
Even with about 70 percent of adults having been fully vaccinated, new case numbers are rising as the weather grows colder in Northern states. Public health officials have begun to warn that another surge could be coming. Pfizer said its new treatment reduced hospitalizations and deaths by 89 percent in high-risk people. It must be taken within three days of the onset of symptoms, which requires access to quick test results.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. expected to purchase 10 million courses of Pfizer COVID-19 pill - WaPoEarlier this month, Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, said the pill https://reut.rs/3oxaxnz cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial. Pfizer expects to submit interim trial results for the pill, branded Paxlovid, to the Food and Drug Administration (FDA) before the Nov. 25 U.S. Thanksgiving holiday.
Read more »
Pfizer agrees to let other companies make its COVID-19 pillLONDON (AP) — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.
Read more »
Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pillPfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill.
Read more »
Pfizer agrees to let other companies make its COVID-19 pillDrugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population. In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population. “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
Read more »
Pfizer agrees to let other companies make its Covid pill to allow broader global accessDrugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental Covid-19 pill, a move that could make the treatment available to more than half of the world’s population.
Read more »